PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 71.2

Change

+0.03 (+0.04)%

Market Cap

N/A

Volume

4.60K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.26 (-0.17%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.02 (-0.03%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.02 (-0.02%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.11 (-0.12%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.09 (-0.38%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.40 (+1.07%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.43 (+0.44%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.05 (-0.17%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.19 (-0.29%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.22 (+0.76%)

USD 0.01B

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.14% 19% F 54% F
Dividend Return 0.05% 7% C- 1% F
Total Return 8.19% 19% F 45% F
Trailing 12 Months  
Capital Gain 21.75% 81% B- 71% C-
Dividend Return 0.06% 11% F 1% F
Total Return 21.81% 81% B- 64% D
Trailing 5 Years  
Capital Gain 41.33% 48% F 68% D+
Dividend Return 0.09% 11% F 1% F
Total Return 41.42% 43% F 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 6.02% 43% F 59% D-
Dividend Return 6.03% 43% F 51% F
Total Return 0.01% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 20.97% 38% F 50% F
Risk Adjusted Return 28.77% 43% F 47% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.